New Delhi, May 5 (UNI) British drug maker GlaxoSmithKline (GSK) Pharma today said it has made a collaboration agreement with Japan-based Astellas Pharma Inc for exclusive rights for the latter's Injectable anti-fungal agent Micafungin in the Indian market.
Micafungin, an original research product of Astellas, was initially approved by Japanese Agency in 2002, by the USEDA in 2005 followed by other countries.
GSK India Managing Director Hasit Joshipura said, ''one of our growth planks is to partner with global pharmaceutical companies for licencing in important molecules. The agreement with Astellas is in line with this strategy of ours.'' Strengthening GSK's presence in Intensive Care, Micafungin also provides an excellent fit with oncology where GSK has a promising R&D pipeline, said Mr Ravi Limaye, Vice President, Pharmaceuticals, GSK India.
Micafungin belongs to a new class of anti-fungal agents that work against deep seated Candida infections. It has a novel mode of action and is indicated for the treatment of patients with Esophageal Candidiasis and the prophylaxis of Candida Infections in patients undergoing Hematopoietic Stem Cell Transplantation in the US.
It works by interfering with the formation of the cell wall of the fungus, which results in the death of the fungus.
In January this year, the USEDA also granted approval for the use of Micafungin in the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses.
UNI SBA SLD KP1317